Duchenne氏肌肉失養症治療市場：依治療方法/治療方法、最終用戶和地區分類

Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, By End User, and By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 169 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，Duchenne氏肌肉失養症治療市場規模將達到 133.078 億美元，到 2033 年將達到 2,074.742 億美元。預計從 2026 年到 2033 年，該市場將以 48.0% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	133.78億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	48.00%	2033年市場規模預測：	2074.742億美元

Duchenne氏肌肉失養症（DMD）是一種肌肉萎縮症。它是一種遺傳性疾病，其特徵是由於一種名為「肌肉Dystrophin」的蛋白質異常而導致進行進行性肌肉萎縮和無力。肌肉營養不良蛋白在維持肌肉細胞的健康狀態中扮演重要角色。 DMD會影響肌肉，導致肌肉萎縮，並隨著時間的推移而加重。Duchenne氏肌肉失養症主要影響男性，但在極少數情況下也會發生在女性身上。

市場動態

Duchenne氏肌肉失養症(DMD) 的日益普遍、對新藥和治療方法的需求不斷成長、研發投入活性化以及公眾對 DMD 和現有藥物及治療方法的認知不斷提高，預計將成為全球Duchenne氏肌肉失養症治療市場成長的主要促進因素。

例如，2022 年 5 月，Stealth Biotherapeutics 宣布，美國食品藥物管理局(FDA) 已授予 ellamipretide 孤兒藥資格，用於治療Duchenne氏肌肉失養症(DMD)。

此外，輝瑞公司計劃於 2022 年 4 月開設美國首個試驗設施，用於對其在臨床實驗的微型肌肉Dystrophin基因療法「Fordadystrogen Movaparbovek」進行 III 期試驗，該療法針對的是能夠行走的Duchenne氏肌肉失養症(DMD) 患者。

本研究的關鍵特徵

本研究揭示了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究基於公司亮點、產品系列、主要特點、財務表現和策略等參數，分析了全球Duchenne氏肌肉失養症治療市場的主要參與者。
透過利用本報告中的見解，企業行銷負責人和經營團隊可以就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球Duchenne氏肌肉失養症治療市場」報告旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球Duchenne氏肌肉失養症治療市場中使用的各種策略矩陣輕鬆做出決策。

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 13,307.8 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	48.00%	2033 Value Projection:	USD 207,474.2 Mn

Duchenne muscular dystrophy (DMD) is a form of muscular dystrophy. It is a genetic disorder characterized by progressive muscle degeneration and weakness due to alterations of a protein called dystrophin, which helps keep muscle cells intact. DMD affects the muscles, leading to muscle wasting that gets worse over time. Duchenne muscular dystrophy occurs primarily in males, though in rare cases may affect females.

Market Dynamics

Increase in prevalence of Duchenne muscular dystrophy (DMD), increase in demand for novel drugs or therapies, rise in research and development (R&D), and increase in awareness among people about DMD and available drugs/therapies are major factors expected to augment growth of the global Duchenne muscular dystrophy treatment market.

For instance, In May 2022, Stealth BioTherapeutics Corp. announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to Elamipretide for the treatment of Duchenne Muscular Dystrophy (DMD).

Moreover, in April 2022, Pfizer Inc. planned to open the first U.S. sites in the Phase III study evaluating investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne Muscular Dystrophy (DMD).

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global Duchenne muscular dystrophy treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., BioMarin, Sarepta Therapeutics, Santhera Pharmaceuticals, PTC Therapeutics, Fibrogen Inc., NS Pharma Inc., Nobelpharma Co. Ltd., Bristol-Myers Squibb, and Eli Lilly and Company.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global Duchenne muscular dystrophy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Duchenne muscular dystrophy treatment market.

Market Segmentation

Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type (Revenue, USD Mn, 2021 - 2033)
Molecular-based Therapies
Steroid Therapy
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Other Therapeutic Approaches and Treatment Types
Global Duchenne Muscular Dystrophy Treatment Market, By End User (Revenue, USD Mn, 2021 - 2033)
Hospitals/Clinics
Ambulatory Centers
Other End Users
Regional Insights (Revenue, USD Mn, 2021 - 2033)
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Company Profiles
Pfizer Inc.
Fibrogen Inc.
BioMarin
Sarepta Therapeutics
Santhera Pharmaceuticals
PTC Therapeutics
NS Pharma Inc.
Nobelpharma Co. Ltd.
Bristol-Myers Squibb
Eli Lilly and Company

Market Dynamics
- Rise in prevalence of Duchenne muscular dystrophy
- Lack of standardization and stringent rules/regulations
- Increase in demand for novel drugs or therapies
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Duchenne Muscular Dystrophy Treatment Market, By Therapeutic Approach and Treatment Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Molecular-based Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
Steroid Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
Other Therapeutic Approaches and Treatment Types
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)

5. Global Duchenne Muscular Dystrophy Treatment Market, By End User, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospitals/Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
Ambulatory Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)
Other End Users
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(USD Mn)

6. Global Duchenne Muscular Dystrophy Treatment Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Approach and Treatment Type, 2021 - 2033,(USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(USD Mn)

7. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Fibrogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
BioMarin
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sarepta Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Santhera Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
PTC Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
NS Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Nobelpharma Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views